Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense
Plus Therapeutics Inc (NASDAQ:PSTV) has been selected for $3 million in funding recommendation by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs. The
Plus Therapeutics Says 'Plus Now Has $23 Million in Active Awards Support for the Company's Targeted Radiotherapeutic Pipeline'
Plus Therapeutics Says 'Plus Now Has $23 Million in Active Awards Support for the Company's Targeted Radiotherapeutic Pipeline'
Press Release: Plus Therapeutics Receives $3 Million Award Recommendation From the United States Department of Defense
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense Plus now has $23 million in active awards support for the Company's targeted radiotherapeutic p
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team
The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus' scient
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced
Buy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry Tailwinds
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Milestone Pharmaceuticals (MIST)
Plus Therapeutics Faces Nasdaq Delisting Over Equity Shortfall
Plus Therapeutics CEO's Insightful Presentation Now Available
Scania Accelerates Deployment of Autonomous Hub-to-hub Transport
SÖDERTÄLJE, Sweden, March 12, 2024 /PRNewswire/ -- Launch of Autonomous Commercial Pilot Programme, with plans for autonomous solution powered by the leading technology stack from Plus. Scania is
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
A total of 18 patients have been dosed in the trial to date Company anticipates moving into Cohort 6 in Q2 2024 following standard safety review AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics,
Buy Rating Affirmed for Plus Therapeutics Amid Strong Financials and Promising Clinical Trials
Plus Therapeutics Is Worried About This – Should You Be Worried Too?
Earnings Call Summary | Plus Therapeutics(PSTV.US) Q4 2023 Earnings Conference
The following is a summary of the Plus Therapeutics, Inc. (PSTV) Q4 2023 Earnings Call Transcript:Financial Performance:Plus Therapeutics reported a decrease in cash reserves to $8.6 million by the en
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
Recap: Plus Therapeutics Q4 Earnings
Plus Therapeutics (NASDAQ:PSTV) reported its Q4 earnings results on Tuesday, March 5, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsPlus Therapeutics beat estimate
Plus Therapeutics FY23 Loss $13.3M >PSTV
Plus Therapeutics FY23 Loss $13.3M >PSTV
Plus Therapeutics: Financial Forecast for Sufficient Runway to Fund Ops Into 2H 2025 >PSTV
Plus Therapeutics: Financial Forecast for Sufficient Runway to Fund Ops Into 2H 2025 >PSTV
Earnings Scheduled For March 5, 2024
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. • Target (NYSE:TGT) is estimated to report quarterly earnings
Plus Therapeutics Earnings Preview
Plus Therapeutics (NASDAQ:PSTV) is set to give its latest quarterly earnings report on Tuesday, 2024-03-05. Here's what investors need to know before the announcement.Analysts estimate that Plus Thera
No Data